MedPath

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC

Phase 3
Conditions
Colorectal Cancer
Interventions
First Posted Date
2013-12-31
Last Posted Date
2015-09-28
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
240
Registration Number
NCT02024412
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer

Phase 3
Conditions
Gastric Cancer
Interventions
First Posted Date
2013-12-31
Last Posted Date
2015-09-28
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
240
Registration Number
NCT02024438
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake

Phase 1
Conditions
Thyroid Diseases
Interventions
Drug: chinese herbs-I
Drug: chinese herbs-II
First Posted Date
2013-06-07
Last Posted Date
2016-02-17
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
400
Registration Number
NCT01873014

Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia

Phase 2
Conditions
Nosocomial Pneumonia
Interventions
Drug: E Group
Drug: C Group
First Posted Date
2013-02-22
Last Posted Date
2016-02-17
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
50
Registration Number
NCT01796717
Locations
🇨🇳

TianjinCIH, Tianjin, Tianjin, China

A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy

Not Applicable
Conditions
Osteosarcoma
Interventions
First Posted Date
2013-01-01
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
40
Registration Number
NCT01758666

A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma

Phase 4
Conditions
Multiple Drug Use
Interventions
Biological: Licartin and CIK
First Posted Date
2013-01-01
Last Posted Date
2016-02-17
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
120
Registration Number
NCT01758679
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)

Phase 2
Conditions
Small Cell Lung Cancer
Interventions
Other: concurrent chemo-radiotherapy arm
First Posted Date
2012-12-10
Last Posted Date
2016-05-17
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT01745445
Locations
🇨🇳

Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR

Phase 2
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2012-12-07
Last Posted Date
2017-02-07
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
60
Registration Number
NCT01744925
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice

Phase 3
Conditions
Postoperative Complications
Interventions
Procedure: preoperative biliary drainage
First Posted Date
2012-12-07
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
136
Registration Number
NCT01744938

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Phase 1
Conditions
Malignant Solid Tumors
Interventions
Biological: MAGE-A4 TCR Gene-Modified T Cells
First Posted Date
2012-09-27
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
15
Registration Number
NCT01694472
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath